Alector, Inc. (NASDAQ:ALEC) Position Reduced by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC lowered its holdings in Alector, Inc. (NASDAQ:ALECFree Report) by 65.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 58,756 shares of the company’s stock after selling 111,442 shares during the period. Los Angeles Capital Management LLC owned approximately 0.06% of Alector worth $469,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of ALEC. New York State Common Retirement Fund boosted its stake in shares of Alector by 104.9% during the 4th quarter. New York State Common Retirement Fund now owns 25,758 shares of the company’s stock valued at $206,000 after buying an additional 13,189 shares during the period. Cookson Peirce & Co. Inc. bought a new stake in shares of Alector during the 4th quarter worth about $160,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Alector by 3.6% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 61,239 shares of the company’s stock valued at $489,000 after acquiring an additional 2,120 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Alector by 352.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,733 shares of the company’s stock valued at $78,000 after acquiring an additional 7,584 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new stake in Alector in the 4th quarter worth approximately $133,000. 85.83% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Alector

In other Alector news, CEO Arnon Rosenthal sold 18,837 shares of Alector stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $6.92, for a total transaction of $130,352.04. Following the transaction, the chief executive officer now directly owns 2,000,380 shares of the company’s stock, valued at approximately $13,842,629.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider Gary Romano sold 6,001 shares of the stock in a transaction on Monday, March 4th. The shares were sold at an average price of $6.92, for a total transaction of $41,526.92. Following the transaction, the insider now directly owns 196,313 shares of the company’s stock, valued at $1,358,485.96. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Arnon Rosenthal sold 18,837 shares of the business’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $6.92, for a total transaction of $130,352.04. Following the sale, the chief executive officer now owns 2,000,380 shares of the company’s stock, valued at approximately $13,842,629.60. The disclosure for this sale can be found here. Insiders sold a total of 30,554 shares of company stock valued at $211,434 in the last quarter. Insiders own 14.00% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. HC Wainwright decreased their price objective on shares of Alector from $41.00 to $35.00 and set a “buy” rating for the company in a report on Thursday. Cantor Fitzgerald restated an “overweight” rating on shares of Alector in a report on Thursday. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $14.00.

Check Out Our Latest Stock Analysis on ALEC

Alector Stock Up 1.0 %

Shares of ALEC opened at $5.25 on Friday. The company has a 50 day moving average of $5.78 and a 200-day moving average of $6.13. Alector, Inc. has a twelve month low of $3.66 and a twelve month high of $9.06. The stock has a market capitalization of $506.02 million, a P/E ratio of -3.80 and a beta of 0.82.

Alector (NASDAQ:ALECGet Free Report) last issued its quarterly earnings data on Tuesday, February 27th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.31. Alector had a negative return on equity of 71.80% and a negative net margin of 125.11%. The company had revenue of $15.19 million during the quarter, compared to analysts’ expectations of $8.35 million. On average, sell-side analysts anticipate that Alector, Inc. will post -1.89 earnings per share for the current fiscal year.

Alector Company Profile

(Free Report)

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.

Further Reading

Want to see what other hedge funds are holding ALEC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alector, Inc. (NASDAQ:ALECFree Report).

Institutional Ownership by Quarter for Alector (NASDAQ:ALEC)

Receive News & Ratings for Alector Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alector and related companies with MarketBeat.com's FREE daily email newsletter.